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Abstract
Background: Upon serial passaging of mouse skeletal muscle cells, a small number of cells will
spontaneously develop the ability to proliferate indefinitely while retaining the ability to
differentiate into multinucleate myotubes. Possible gene changes that could underlie myogenic cell
immortalization and their possible effects on myogenesis had not been examined.
Results: We found that immortalization occurred earlier and more frequently when the myogenic
cells lacked the pro-apoptotic protein Bax. Furthermore, myogenesis was altered by Bax
inactivation as Bax-null cells produced muscle colonies with more nuclei than wild-type cells,
though a lower percentage of the Bax-null nuclei were incorporated into multinucleate myotubes.
In vivo, both the fast and slow myofibers in Bax-null muscles had smaller cross-sectional areas than
those in wild-type muscles. After immortalization, both Bax-null and Bax-positive myogenic cells
expressed desmin, retained the capacity to form multinucleate myotubes, expressed p19ARF protein,
and retained p53 functions. Expression of p16INK4a, however, was found in only about half of the
immortalized myogenic cell lines.
Conclusions: Mouse myogenic cells can undergo spontaneous immortalization via a mechanism
that can include, but does not require, loss of p16INK4a, and also does not require inactivation of
p19ARF or p53. Furthermore, loss of Bax, which appears to be a downstream effector of p53,
accelerates immortalization of myogenic cells and alters myogenesis.
Background
Under cell culture conditions in which almost all primary
mouse cells cease proliferation after 10 – 30 population
doublings in serial subcultures, a small number of cells
escape this proliferation block, spontaneously immortal-
ize, and continue to proliferate indefinitely. Many types of
mouse cells undergo this spontaneous immortalization,
including fibroblasts obtained from mouse embryos and
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myogenic cells obtained from skeletal muscles [1-3]. In
the case of myogenic cells, immortalization does not
impair the ability of the cells to respond to differentiation
signals by ceasing to proliferate and fusing to form multi-
nucleate myotubes [1,3]. Such immortalized myogenic
cell lines have been very valuable in studies of myogene-
sis, but the molecular alterations underlying myogenic
cell immortalization have not been examined. In this
study, we examine the mechanisms of myogenic cell
immortalization and differentiation with a focus on apop-
tosis regulators. We focused on apoptosis regulators
because we have found that myogenic cells express several
members of the Bcl-2 family of apoptosis regulators and
that Bcl-2 is required for normal fast myofiber develop-
ment [4,5]. Furthermore, muscle cell apoptosis is found in
diseased and injured muscle [6,7]. Finally, inactivation of
apoptosis pathways, including inactivation of members of
the p53 and pRb pathways, is one possible route to cell
immortalization [8].
The molecular and cellular mechanisms which allow
some types of mouse cells to circumvent proliferation lim-
its in vitro have begun to be identified. For example,
improved culture conditions allow some types of rodent
cells to circumvent this usual replication limit and con-
tinue to proliferate indefinitely [9-11]. Inadequate culture
conditions may produce stress-related changes in rodent
cells that rapidly lead to cessation of growth, a mechanism
distinct from the cessation of growth due to telomere
shortening seen with cultured human cells [8,12,13].
Even under culture conditions that do not support long-
term growth of most cells, however, immortalization of
mouse cells can occur upon inactivation of one or more
cell cycle regulators including p19ARF, p53, or the Cyclin
D regulator p16INK4a. For example, mouse embryo fibrob-
lasts and pre-B cells escape proliferation limits and grow
indefinitely upon inactivation of either p19ARF or p53
[2,14-16]. Some cell types, such as mouse bone marrow
macrophages, immortalize upon inactivation of p16INK4a
rather than p19ARF or p53 [15]. Inactivation of p16INK4a
also accelerates immortalization of mouse embryo fibrob-
lasts [17]. On the other hand, mouse cells that are defi-
cient in DNA repair due to mutation of ATM, Brca2, Ku80,
XPG, or Ligase IV cease replicating even sooner than wild-
type cells in culture [8]. These results have raised the pos-
sibility that spontaneous immortalization of rodent cells
under inadequate culture conditions may require inacti-
vation of either the p16INK4a-regulated Cyclin D/Rb path-
way or the p19ARF/p53 pathway that responds to DNA
damage by inducing apoptosis [8].
Though immortalized myogenic cells will proliferate
indefinitely under high serum conditions or at low den-
sity, these cells retain the ability of non-immortalized
myoblasts to respond to low serum or high density by
ceasing proliferation and fusing to form multinucleate
myotubes in which the myonuclei are post-mitotic. Thus,
myogenic cell immortalization must occur via molecular
alterations that promote continued proliferation without
impairing differentiation. With respect to the p53 and
pRb pathways, myogenesis is known to proceed normally
in p53-null mice in vivo and with a moderately lowered
fusion index in p53-null myoblasts in vitro [18,19],
whereas myogenesis is highly impaired in pRb-null mice
in vivo and by pRb-null myoblasts in vitro [20,21].
Though loss of p53 pathway function thus appears com-
patible with immortalization of myogenic cells, at least
one mouse myogenic cell line, C2C12, has previously been
shown to have normal p53 function [22].
Several lines of evidence suggest that the response of
rodent cells to culture conditions may be under control of
apoptosis regulators that are downstream of p19ARF/p53,
particularly the pro-apoptotic protein Bax. First, cells that
lose the capacity to proliferate in culture often undergo
apoptosis, a process that is regulated in many cases by
members of the Bcl-2 family, including Bax which pro-
motes apoptosis [8,23]. Second, Bax appears to act down-
stream of p53 in the apoptotic pathway. For example, p53
and Bax undergo nuclear translocation upon chemother-
apy-induced apoptosis in human melanoma cells [24];
and inactivation of p53 prevents Bax translocation upon
apoptosis induction in embryonic neurons [25]. Studies
of tumorigenesis in double knock-out mice also suggest
that Bax acts downstream of p53 [26], and inactivation of
Bax alters the tumor type and number, though not age of
tumor appearance, in p19ARF-null mice [27].
In this study, we found that, unlike mouse embryo fibrob-
lasts, mouse myogenic cells undergo spontaneous immor-
talization via a mechanism that does not require
inactivation of p19ARF or loss of p53 functions. In some,
but not all cases, immortalization of muscle lines was
accompanied by loss of p16INK4a. Furthermore, we identi-
fied a new mechanism, inactivation of Bax, that acceler-
ates the immortalization of mouse myogenic cells. We
also found that Bax functions in myogenesis, because Bax-
null myogenic cells produced relatively more mononucle-
ate cells and fewer multinucleate myotubes than wild-type
myogenic cells in culture, and the myofibers in Bax-null
muscles in vivo were smaller than those in wild-type mus-
cles. Thus, we find that mouse postnatal myogenic cells
can spontaneously immortalize by a different mechanism
than mouse embryo fibroblasts; that inactivation of Bax
accelerates immortalization of myogenic cells, and that
Bax functions in regulation of myogenesis.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/1
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Results
During derivation of spontaneously immortalized mouse
myogenic cell lines, we found that myogenic cells from
homozygous Bax-null mice immortalized more rapidly in
culture than myogenic cells from wild-type or hetero-
zygous Bax (+/-) mice, though not as rapidly as myogenic
cells from p53-null mice (Fig. 1). In multiple independent
experiments, skeletal muscles were obtained from
homozygous-null Bax (-/-), heterozygous Bax (+/-), and
wild-type Bax (+/+) littermates at 4 – 6 weeks after birth.
The muscles were individually dissociated to produce sin-
gle cell suspensions, and primary cultures of the Bax (-/-),
Bax (+/-), and Bax (+/+) muscle cells were established and
serially passaged as described in Materials and Methods.
For comparison, a serial culture was also prepared using
muscle cells from similarly aged p53 (-/-) mice, because
previous work showed that mouse embryo fibroblasts are
immortalized upon inactivation of p53 [14].
In Figure 1, we show results from three separate experi-
ments in which we started four independent cultures of
Bax-null myogenic cells. Each of these cultures produced
immortalized Bax-null cells at no later than 30 days after
the beginning of the experiment (Fig. 1, Expts. 1 – 3). In
contrast, only one of the three wild-type, and neither of
the two heterozygote, cultures produced immortalized
cells; and the one line of immortalized wild-type cells that
did arise was not produced until ~40 days after the begin-
ning of the experiment (Fig. 1, Expt. 3). The Bax-null, het-
erozygous, and wild-type myogenic cells all showed an
early period of rapid growth lasting about ten days (3 – 4
passages), which was followed by a plateau period of
slower or no growth in the wild-type and heterozygous
cultures. In Bax-null cultures, the early period of fast
growth was followed by either a similar, though shorter,
plateau period of slower or no growth (Fig. 1; Expts. 2 and
3) or by little change in growth rate (Fig. 1; Expt. 1). We
found immortalized cells by day 50 of culture in 7 of 7
Bax-null cultures, but in only 3 of 9 Bax-positive cultures
which included 1 of 4 Bax (+/-) cultures and 2 of 5 Bax (+/
+) cultures (P = 0.011 by Fisher's exact test comparing Bax-
null to Bax-positive results). As noted before [4], loss of
Bax is not required for immortalization, because sponta-
neously immortalized wild-type and Bax (+/-) hetero-
zygous myogenic cells, as well as NIH3T3 cells, retained
Bax protein expression (Fig. 5 and not shown).
Because p53-null mouse embryo fibroblasts immortalize
very efficiently [14], we also examined proliferation of
p53-null myogenic cells. The p53-null myogenic cells,
similar to the p53-null mouse embryonic fibroblasts [14],
showed rapid growth without the period of slower growth
seen in the Bax-null and wild-type cells (Fig. 1, Expt. 3).
The proliferation rate of the immortalized myogenic cells
appeared to be independent of genotype, because the
immortalized Bax-null, p53-null, and wild-type cells all
had a proliferation rate at 60 days of culture of approxi-
mately one doubling per day.
Immortalized Bax-null, p53-null, and wild-type muscle
cells taken from rapidly growing, late passage cultures
grew in clonal cultures at high efficiency, with >50% of
single cells forming colonies after cloning. Starting with
muscle-derived cells from long-term (>20 passages) cul-
tures, we used two rounds of cloning to obtain multiple
independent cell lines of different genotypes (Bax-null,
p53-null, wild-type). These lines of immortalized cells
were further characterized and compared to cells in pri-
mary, non-clonal cultures at early passage (<4 passages).
Immortalized and cloned Bax-null cells retained many
molecular and functional properties of satellite cell myob-
lasts. In particular, when proliferating at low density, the
immortalized Bax-null cells expressed desmin and had the
typical bipolar morphology of myoblasts (not shown). In
the clonal lines, all of the cells expressed desmin, whereas
some cells in the primary cultures, which were not cloned
and thus contained a mixture of myogenic and non-myo-
genic cells, did not express desmin. Upon reaching conflu-
ence, Bax-null cells of the clonal lines fused and formed
myosin-expressing, multinucleate myotubes (not shown).
The clonal lines derived from p53-null and wild-type cells
similarly showed desmin expression and the ability to
form multinucleate myotubes. Multinucleate myotubes
formed by Bax-null, wild-type, and p53-null cells
appeared to have identical morphologies.
The immortalized and cloned Bax-null myogenic cells
failed to grow in soft agar, suggesting that they were not
tumorigenic, and they did not express SA-β-Gal, suggest-
ing that they were not senescent and/or "stressed" [8]. In
addition, the immortalized and cloned Bax-null cells did
not express either Sca-1 or Bcl-2, two proteins that appear
to mark muscle-derived cells that are at an early stage of
myogenesis or have stem cell-like properties [4,5,28-32].
In contrast, a small proportion (~1–5%) of the desmin-
positive cells in uncloned primary cultures did express the
Sca-1 and Bcl-2 proteins (not shown), just as in previous
work [4,5].
Though both non-immortalized (early passage) and
immortalized Bax-null cells were capable of forming
multinucleate myotubes in culture, the percentage of
nuclei in multinucleate cells (the fusion index) was lower
in Bax-null than in wild-type clonal cultures (Table 1 and
not shown). A similar reduction in fusion index was seen
in differentiated cultures of p53-null myoblasts (not
shown), a result also seen in an earlier study [19]. When
grown at high density and allowed to form multinucleate
cells upon reaching confluence in growth medium, weBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/1
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Cells derived from Bax-null muscles immortalized more rapidly than cells from Bax-positive muscles Figure 1
Cells derived from Bax-null muscles immortalized more rapidly than cells from Bax-positive muscles. Primary cultures of Bax (-
/-); Bax (+/-); Bax (+/+); and p53 (-/-) myogenic cells were established, serially passaged, and enumerated at each passage as 
described in Materials and Methods. Results of three independent experiments are shown. As described in the text, myogenic 
cells from Bax-null muscles (closed circles) immortalized more rapidly and more frequently than myogenic cells from either 
Bax (+/-) heterozygous muscles (crossed circles) or Bax (+/+) wild-type muscles (open circles). However, myogenic cells from 
p53 (-/-) muscles (stars with dotted line in Expt. 3) immortalized faster than Bax-null cells without showing the temporary pla-
teau in growth rate shown by Bax-null cells. Each symbol denotes a time at which cells were collected and passaged onto new 
culture dishes as described in Materials and Methods.
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saw the same lower fusion index for Bax-null than for Bax-
positive cells as when the cells were grown at clonal den-
sity (not shown).
This difference in fusion index appeared to be due to a
higher number of mononucleate cells, rather than a lower
number of nuclei in myotubes, in the Bax-null cultures.
For example, muscle colonies formed by the progeny of
individual Bax-null cells contained both significantly
more total nuclei and significantly more mononucleate
cells than those formed by Bax-positive cells (Table 1). In
contrast, neither the average number of nuclei per multi-
nucleate myotube (Table 1) nor the average number of
myotubes per colony (not shown) differed between Bax-
positive and Bax-null colonies.
To determine if Bax functions to regulate apoptosis in
myogenic cells, as it does in other cell types, we compared
the response of Bax-null and Bax-positive myogenic cells
to three treatments that can induce apoptosis: exposure to
adriamycin (doxorubicin), staurosporine, or serum-free
medium [11,32]. Bax-null myogenic cells were signifi-
cantly more resistant than Bax-positive cells to cell death
induced both by adriamycin or staurosporine (Fig. 2A)
and by serum-free medium (Fig. 2B). The active, cleaved
form of caspase-3, which was undetectable by immunob-
lot in untreated cultures, appeared more slowly in stau-
rosporine-treated Bax-null cultures than in similarly
treated wild-type cultures (not shown). Additional assays
based on appearance of pyknotic nuclei, propidium
iodide permeability, and annexin V externalization also
showed that Bax-null cells were more resistant to induced
cell death.
To test the possibility that Bax inactivation might affect
muscle development in vivo, we examined muscle fiber
size, density, and fiber type in soleus muscles obtained
from Bax-null and wild-type littermates at seven weeks of
age. Muscles were examined from three pairs of age- and
gender-matched, Bax-null and Bax-positive littermates.
Each pair gave similar results and the aggregated results
are presented in Table 2. The average cross-sectional areas
of both fast and slow myofibers were significantly smaller
in Bax-null than in wild-type soleus muscles. The fast and
slow fibers in the diaphragm were also smaller in Bax-null
than in wild-type mice. Furthermore, the density (number
per mm2) of both fast and slow myofibers was signifi-
cantly higher in Bax-null than in Bax-positive soleus mus-
cles. In contrast, the percentages of fast and slow
myofibers were the same in Bax-null and wild-type soleus
muscles.
To examine possible mechanisms of muscle cell immor-
talization, we analyzed expression and function of three
proteins – p53, p19ARF, and p16INK4a – that when inacti-
vated lead to immortalization of mouse cells in non-myo-
genic lineages. To eliminate the possibility that
spontaneous immortalization of myogenic cells was due
to loss of p53 function, we used three types of experi-
ments, all of which suggested that normal p53 function is
retained after immortalization of both wild-type and Bax-
null myogenic cells. First, we used karyotyping to show
that immortalized Bax-null myogenic cells did not show
the chromosome instability that is seen when p53 func-
tion is lost. Previous work had shown that immortalized
p53-null mouse embryo fibroblasts have about twice as
many chromosomes as p53-positive cells [14]. Multiply
passaged (>20 passages), immortalized wild-type and
Bax-null myogenic cells had the normal number of chro-
mosomes, whereas similarly passaged and immortalized
p53-null myogenic cells had about twice as many chro-
mosomes as the Bax-null and wild-type myogenic cells
(Fig. 3). Second, in cultures at the time that multinucleate
myotube formation was beginning, we found that a pro-
moter fragment that requires p53 for activation was
expressed in immortalized Bax-null and wild-type, but
not in p53-null, myogenic cells (Fig. 4A,4B,4C,4D,4E,4F).
In contrast, a control promoter that did not require p53
function for activation was equally well expressed in Bax-
null, p53-null, and wild-type cells (Fig.
4A,4B,4C,4D,4E,4F). Previous work with the C2C12 line of
myogenic cells, which are Bax-positive [4], had shown
that p53 activity and activation of this promoter fragment
are both upregulated as fusion of myoblasts to form
multinucleate myotubes begins in culture [33]. Finally,
we found that in both Bax-null and Bax-positive immor-
talized myogenic cells p53 protein levels were markedly
upregulated upon actinomycin treatment, which is the
normal response of p53 to this DNA-damaging drug (Fig.
Table 1: Effect of Bax genotype on properties of muscle colonies formed by the progeny of individual myogenic cells in vitro.
Property Bax-positive ave ± SE (n) Bax-null ave ± SE (n) Significance*
Number of nuclei per colony 428 ± 17 (341) 486 ± 22 (303) P < 0.05
Number of mononucleate cells per colony 131 ± 7.0 (341) 191 ± 8.6 (306) P < 0.0001
Percentage of nuclei in multinucleate cells 65.1 ± 0.9 (341) 55.5 ± 1.1 (306) P < 0.0001
Number of nuclei per multinucleate cell 3.9 ± 0.1 (341) 3.9 ± 0.1 (305) P > 0.5
*Unpaired, two-tailed, t-test.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/1
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Bax-null myogenic cells were more resistant than wild-type myogenic cells to cell death induced by adriamycin, staurosporine,  or serum-free medium Figure 2
Bax-null myogenic cells were more resistant than wild-type myogenic cells to cell death induced by adriamycin, staurosporine, 
or serum-free medium. A. Myogenic cells from Bax-null (KO, filled bars) and wild-type (WT, open bars) were grown in culture 
until near confluence and then exposed to either 1.7 µM adriamycin, 50 nM staurosporine, or left untreated as a control. After 
24 h of treatment, the number of viable cells in each culture was determined and expressed as a percentage of the number of 
viable cells in the untreated cultures. After either adriamycin or staurosporine treatment, signficantly more viable cells 
remained in the Bax-null than in the wild-type cultures. Error bars equal SE with n = 4. P values of significance from unpaired, 
two-tailed, t-test. This experiment was repeated an additional two times with similar results. B. Myogenic cells from two inde-
pendent, immortalized Bax-null lines (Bax KO, filled circles) and one immortalized wild-type line (WT, open circles) were 
grown in culture until near confluence and then switched to serum-free medium. After 1 day and 2 days of treatment, the 
number of viable cells in each culture was determined and expressed as a percentage of the number of viable cells on day 0 
when the medium switch was made. After both one and two days in serum-free medium, significantly more viable cells 
remained in the each of the Bax-null cultures than in the wild-type culture (P < 0.001 by Welch alternate T-test as indicated by 
***). In constrast, the two Bax KO experiments did not differ significantly from each other. Error bars equal SE with n = 12 to 
24.
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4G). Levels of the p53-inducible protein p21Cip1 were also
raised as expected by actinomycin treatment (not shown).
Thus, immortalized wild-type and Bax-null myogenic
cells had normal p53 function as assayed by maintenance
of normal karyotype, promoter activation, and induction
by actinomycin.
In addition to normal p53 function, immortalized myo-
genic cells continued to express p19ARF protein (Fig. 5).
For p19ARF assays, we examined expression in primary cul-
tures (not immortalized) of myogenic cells obtained from
postnatal skeletal muscle, and in cultures of spontane-
ously immortalized mouse embryonic fibroblasts
(NIH3T3), wild-type postnatal myogenic cells, and Bax-
null postnatal myogenic cells. Immunoblotting showed
that, as expected [2], NIH3T3 cells did not express detect-
able amounts of p19ARF; however, p19ARF was present in
all Bax-null and wild-type myogenic cells, including both
early passage primary cells and late passage immortalized
cells (Fig. 5). The amount of p19ARF protein appeared to
be increased in both Bax-null and wild-type immortalized
myogenic cells, a result also seen in late passage, wild-type
mouse embryo fibroblasts [34].
In contrast to p53 and p19ARF, which were found in all
tested myogenic lines, p16INK4a was deleted in two of the
four Bax-null myogenic lines that were examined (Fig. 5).
As found previously in mouse embryo fibroblasts [2], we
found that p16INK4a protein was undetectable in rapidly
growing cultures of early passage (not immortalized)
mouse myogenic cells (Fig. 5), but became highly
expressed when the cultures reached the slow growing
"crisis" stage after 4–5 passages (not shown). After
immortalization, we found that p16INK4a was expressed by
two independently-derived Bax-null myogenic lines and
one Bax-positive line but was not expressed in two addi-
tional Bax-null lines (Fig. 5 and not shown). Thus,
immortalization was accompanied by lack of p16INK4a
expression in some, but not all, myogenic cell lines.
Discussion
We found that mouse myogenic cells can undergo sponta-
neous immortalization via a mechanism that can include,
but does not require, loss of p16INK4a protein expression,
and also does not require loss of p19ARF protein or p53
function. Furthermore, we identified a new mechanism,
inactivation of Bax, that accelerates the immortalization
of mouse myogenic cells. We also found that Bax-null
myogenic cells produced relatively more mononucleate
cells than wild-type myogenic cells in culture and that the
myofibers in Bax-null muscles in vivo were smaller than
those in wild-type muscles. We discuss these findings
below.
Mouse embryo fibroblasts and some immune cells are
highly dependent on either mutations of p53 or deletions
of p19ARF to escape replicative limits in culture [2,14-16].
In contrast, we did not find such alterations in immortal-
ized myogenic cells, whether Bax-positive or Bax-null,
suggesting that immortalization of postnatal myogenic
cells and embryonic fibroblasts can occur by different
mechanisms. As shown previously, spontaneously
immortalized myogenic cell lines that are derived from
wild-type mouse cells typically retain p53 function
[19,22,33,35] and Bax protein expression [4]. Here we
showed that immortalized Bax-null myogenic cells also
retained p53 functions, as well as p19ARF protein. Cell
cycle checkpoints required for ceasing mitosis and
differentiation were also normal in immortalized myo-
genic cells, because both Bax-positive and Bax-null cells
were able to cease dividing and form multinucleate myo-
tubes that contained post-mitotic myonuclei.
Inactivation of p16INK4a, which occurred in some myo-
genic cell lines, also leads to immortalization of macro-
phages [15] and accelerated immortalization of mouse
embryo fibroblasts [17]. Inactivation of p16INK4a is also
associated with establishment of immortalized cell lines
from mouse liver and lung epithelial tissues [36,37].
Though deletion of their overlapping reading frames often
Table 2: Effect of Bax genotype on properties of myofibers in vivo.
Property Muscle Bax-positive ave ± SE (n) Bax-null ave ± SE (n) Significance*
Cross-sectional area (µm2) of fast‡ myofibers Soleus 1045 ± 17.0 (451) 785 ± 11.9 (500) P < 0.0001
Diaphragm 873 ± 7.7 (1364) 717 ± 6.9 (1570) P < 0.0001
Cross-sectional area (µm2) of slow‡ myofibers Soleus 1399 ± 33.7 (193) 1096 ± 16.6 (270) P < 0.0001
Diaphragm 640 ± 15.0 (136) 547 ± 12.8 (150) P < 0.0001
Percentage of fast myofibers Soleus 70.2 ± 1.8 (3) 70.8 ± 0.1 (3) P > 0.7
Diaphragm 90.7 ± 0.7 (5) 91.2 ± 0.8 (5) P > 0.7
Cross-sectional area (mm2) of whole muscle Soleus 1.54 ± 0.12 (4) 1.18 ± 0.06 (5) P = 0.024
Total number of myofibers Soleus 1081 ± 36 (4) 1102 ± 17 (5) P > 0.5
‡Fast and slow myofibers were identified by ATPase staining as described in Methods. *Comparison of Bax-positive to Bax-null with unpaired, two-
tailed, t-test.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/1
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Immortalized Bax-null myogenic cells had normal chromosome numbers Figure 3
Immortalized Bax-null myogenic cells had normal chromosome numbers. Chromosome numbers of individual cells were deter-
mined in (i) primary cultures of two independent, early passage number <4, wild-type myogenic cells (n = 66); (ii) late passage 
cultures of two independent, immortalized, Bax-null myogenic lines (n = 49); and (iii) a late passage culture of one line of 
immortalized p53-null myogenic cells (n = 32). (In this and subsequent figures, late passage, immortalized lines were examined 
at passage numbers 17 – 26 corresponding to >60 days of total culture duration; and early passage, non-immortalized lines 
were examined at passage numbers < 4 corresponding to less than 12 days of total culture duration and prior to the slow 
growth period.) Pooled results are shown for the two wild-type and the two Bax-null lines (BaxKO lines #1 and #2, see also 
Figs. 4 and 5), because, in each case, the two lines had statistically identical chromosome numbers. Both wild-type and Bax-null 
myogenic cells had normal karyotypes with approximately 40 chromosomes, whereas p53-null myogenic lines had approxi-
mately twice the normal number of chromosomes.
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Activation of a p53-dependent promoter and induction by Actinomycin D were normal in immortalized Bax-null myogenic cells Figure 4
Activation of a p53-dependent promoter and induction by Actinomycin D were normal in immortalized Bax-null myogenic 
cells. As indicated in panels A-F, wild-type, immortalized Bax-null, and immortalized p53-null myogenic cells were transfected 
with either PG13-GFP, a plasmid from which GFP expression requires normal p53, or with the control pCMV-β-Gal, a plasmid 
from which β-Galactosidase is expressed independently of p53. GFP was detected by endogenous green fluorescence, and β-
Galactosidase was detected by immunocytochemistry with a specific antibody (red fluorescence). GFP was expressed in wild-
type and Bax-null cells, but not in p53-null cells, whereas β-Galactosidase was expressed in all three cell types. Transfection 
efficiency, measured as percentage of β-Galactosidase-expressing cells, was independent of genotype and ranged from 5.0 – 
15.7% in different experiments. Bar = 20 µm. For panel G, cultures of NIH3T3 cells, two immortalized Bax-null lines (BaxKO-
1 and BaxKO-2), and one immortalized wild-type line (WT-1) were examined by immunoblotting for p53 expression. Expres-
sion of p53 was barely detectable in untreated cultures (ActD-), but was abundant in parallel Actinomycin D-treated cultures. 
Treated cells were exposed to 60 ng/ml of Actinomycin D for 8 hours and cells were collected for immunoblot analysis 16 
hours after the Actinomycin D was removed and replaced with fresh medium.
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leads to simultaneous inactivation of p16INK4a and p19ARF
in cells such as mouse embryo fibroblasts [2], we did not
observe such double inactivation in immortalized mouse
myogenic cells. Promoter-specific hypermethylation is
one mechanism that can inactivate p16INK4a  but not
p19ARF expression [e. g., [37]]. Our results show that myo-
genic cell immortalization can sometimes occur without
loss of the three proteins – p16INK4a, p19ARF, and p53 –
that are typically found to be inactivated upon immortal-
ization of mouse cells of many non-myogenic lineages.
Thus, though loss of p16INK4a protein expression is likely
to be one of the mechanisms underlying myogenic cell
immortalization, further work is needed to identify the
additional mechanisms that appear to exist in mouse
myogenic cells. Though p16INK4ais an indirect regulator of
pRb function, it is unlikely that loss of pRb function itself
can underlie myogenic cell immortalization, because loss
of pRb function causes a drastic loss of muscle differenti-
ation capacity [20,21].
How might the absence of Bax increase the speed and fre-
quency of myogenic cell immortalization? A likely expla-
nation is that many potentially immortal Bax-null cells
can arise and replicate instead of being destroyed by Bax-
dependent cell death. Bax is a pro-apoptotic member of
the Bcl-2 family, and inactivation of Bax can render cells
more resistant to apoptosis, as shown previously for sev-
eral cell types [38,39] and here for myogenic cells (Fig. 2).
Spontaneous immortalization of myogenic cells under
usual (perhaps sub-optimum) culture conditions is a rare
event [1]. Primary cultures of myogenic cells, as well as
other cell types [11,12,15], typically undergo a "crisis"
during which most cells cease replicating, followed by
emergence of the progeny of rare immortalized cells (cf.
Fig. 1, Expt. 3).The mouse C2 myogenic cell line, for
example, was initially derived from such rare spontane-
ously immortalized cells [3]. It may be that many cultured
cells which carry potential immortalizing alterations are
normally subject to apoptosis. Disabling the apoptosis
mechanism, such as by Bax inactivation, would increase
the number of such potentially immortal cells that sur-
vive. Further work is needed to determine if other
mutations that inactivate apoptosis will also increase
myogenic cell immortalization in culture.
Bax inactivation appeared to affect the balance between
myoblast proliferation, survival, and fusion to form
multinucleate myotubes. Differentiated cultures of Bax-
null myogenic cells contained relatively more mononu-
cleate cells, but had a lower fusion rate, than parallel wild-
type cultures. These differences could also arise due to
increased resistance of Bax-null myogenic cells to apopto-
sis. As muscle cell differentiation begins in culture, some
myoblasts typically undergo apoptosis rather than fusing
to form myotubes or surviving in a quiescent state [40-
42]. If myoblasts normally destined for apoptosis at the
beginning of differentiation instead survive but do not
fuse when Bax is inactivated, then Bax-null cultures would
have more mononucleate cells, and relatively fewer multi-
nucleate myotubes, than wild-type cultures. A role for
inhibition of apoptosis in myoblast survival is supported
by the finding that apoptosis of myoblasts is prevented by
the heat shock protein, alpha B-crystallin, which also
inhibits activation of caspase-3 [41].
Though a small percentage of the desmin-positive, myo-
genic cells in Bax-null cultures expressed Sca-1, this pro-
tein was not expressed by immortalized Bax-null
myogenic cells. Expression of the cell surface protein Sca-
1, at least on some muscle-derived cells, appears to
identify rare cells that are at a very early stage of the myo-
genic pathway and may have stem cell properties
Immortalized myogenic cells expressed p19ARF but sometimes  did not express p16INK4a Figure 5
Immortalized myogenic cells expressed p19ARF but sometimes 
did not express p16INK4a. Immunoblotting was used to exam-
ine p16INK4a and p19ARF expression by non-immortalized, rap-
idly growing, Bax-positive myogenic cells (WT Pass 1); 
NIH3T3 cells; two independently-derived lines of immortal-
ized Bax-null myogenic cells (BaxKO-1 and BaxKO-2); and 
one line of immortalized Bax-positive myogenic cells (WT-1). 
Immunoblotting for Bax was used to verify genotypes, and 
immunoblotting for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used to verify that similar amounts of 
protein were analyzed in each lane. As expected [14], 
NIH3T3 cells (immortalized mouse embryo fibroblasts) did 
not express either p16INK4a or p19ARF. Early passage, rapidly 
growing wild-type cells expressed p19ARF but not p16INK4a, 
though p16INK4a was expressed when cells entered "crisis" 
(not shown). The p19ARF protein was expressed by all immor-
talized myogenic cell lines that were examined, whereas the 
p16INK4a protein was expressed by some (e.g., BaxKO-2), but 
not all (BaxKO-1) lines. See text for details.
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[4,28,30-32,44]. Because none of the immortalized Bax-
null myogenic cells expressed Sca-1, it is likely that they
were derived by immortalization of Sca-1-negative myob-
last precursors.
The smaller myofibers in the Bax-null soleus might have
been due to indirect, rather than direct, effects on muscle
development. Unlike Bcl-2 inactivation which leads to a
specific loss of fast myofibers [4], Bax inactivation affects
both fast and slow myofibers equally. Bax (-/-) mice have
normal viability, but have abnormalities in reproductive
cells, lymphoid hyperplasia, and decreased apoptosis dur-
ing development [45,46]. No difference in the growth
rates of Bax-null and Bax-positive mice has been reported,
and skeletal muscles had not previously been examined in
Bax-null mice. In skeletal muscles, the size of myofibers is
regulated by a number of factors, including motor neuron
activity and exercise patterns; protein growth factors such
as growth hormone, IGF1, and myostatin; steroid hor-
mones; availability of muscle precursor cells (myoblasts);
and food intake [47]. Myofiber size in Bax-null muscles
would likely be affected if any of these regulatory factors
is altered by Bax-deficiency. As one possibility, for exam-
ple, excess motor neurons which are eliminated during
neuromuscular development in Bax-positive mice survive
in Bax-null mice [48], which could perhaps lead to inap-
propriate nerve activity and decreased myofiber size. Fur-
ther studies are necessary to determine if Bax inactivation
leads to alterations in factors that indirectly regulate
myofiber size.
A direct, muscle cell autonomous, effect of Bax inactiva-
tion that would produce smaller myofibers is perhaps less
likely. Increased resistance to apoptosis in muscle
precursor cells would seem to be consistent with the pro-
duction of more myogenic cells and larger myofibers. If,
however, Bax-null myoblasts are less likely to fuse in vivo
as in vitro, smaller myofibers could result. In this case,
however, one would then expect to see higher numbers of
myoblasts in Bax-null muscles, but we did not observe an
increased density of nuclei outside of myofibers in Bax-
null muscles (not shown). Studies of mice with muscle-
specific inactivation of Bax, or with muscle-specific
expression of Bax in Bax-null mice could determine
whether Bax inactivation affects myofiber size directly or
indirectly.
Conclusions
We found that mouse myogenic cells can undergo sponta-
neous immortalization via a mechanism that can include,
but does not require, loss of p16INK4a, and also does not
require inactivation of p19ARF or p53. Furthermore, we
identified a new mechanism, inactivation of Bax, that
accelerates the immortalization of mouse myogenic cells.
We also found that Bax-null myogenic cells produced rel-
atively more mononucleate cells and fewer multinucleate
myotubes than wild-type myogenic cells in culture and
that the myofibers in Bax-null muscles in vivo were
smaller than those in wild-type muscles. These results, as
well as our earlier work with Bcl-2 [4,5], implicate Bcl-2
family-mediated processes in controlling the proliferation
and differentiation of myogenic cells. In addition, this
study emphasizes that mouse cells of different lineages
take different routes to immortalization.
Methods
Mice and cell culture
Breeding pairs of heterozygous B6.129X1-Baxtm1Sjk mice
[45] were obtained from the Jackson Laboratory and
mated in our laboratory. Progeny were genotyped [45],
and muscle tissue or cells for primary cultures were
obtained from tissues of the resulting wild-type, hetero-
zygous, and Bax-null littermates at 4–6 weeks of age. At
this age, there was no difference in body weights between
Bax-null and Bax-positive mice. To obtain myogenic cells
for culture, hindlimb muscles were isolated and treated
with pronase to release mononucleate cells as described
[4]. To obtain highly enriched myogenic cell populations,
each mononucleate muscle cell preparation was fraction-
ated by 2-step (35%, 70% Percoll) gradients, and cells
were collected from the 35–70% interface as described
[4,49]. Unless otherwise noted, cells were cultured on ECL
Matrix (Upstate Biotechnology) in proliferation medium
(PM) which consisted of DMEM with 15% horse serum,
4% chicken embryo extract, 2 mM L-glutamine, 10 mM
HEPES pH 7.4, 100 U/ml penicillin, and 1 mM pyruvate.
Myoblasts were induced to differentiate by transfer to dif-
ferentiation medium (DM) which consisted of DMEM
without chicken embryo extract and with only 2% horse
serum.
Cell proliferation and clonal assays
To measure proliferation of cells obtained from adult tis-
sues, myogenic cell cultures were initiated at ~100 cells
per cm2. Growth medium was used at ~0.1 ml per cm2 and
medium was replaced each day with fresh medium. Myo-
genic cells were passaged and reseeded at the initial
density after 3 – 6 days of culture, at which time the cells
had not reached confluence and fusion to form multinu-
cleate myotubes had not begun. For all proliferation
assays, cells were released from the culture dish by treat-
ment with trypsin, and cell numbers were determined
using a hemocytometer to enumerate viable cells that
excluded Trypan Blue (GIBCO-Invitrogen). Cell growth
was also assessed by counting cells per unit area in culture
using an inverted microscope with results equivalent to
those obtained with a hemocytometer.
To determine the properties of clonally-derived muscle
colonies, cultures of myogenic cells that were initiated atBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/1
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clonal density (~1–10 cells/cm2) were fixed with parafor-
maldehyde (see below) after 8 days of growth, immunos-
tained for the muscle-specific intermediate filament
protein desmin (typically >80% of the colonies were com-
posed of cells that were desmin-positive), and examined
to determine the number of nuclei per colony and the per-
centage of nuclei contained within multinucleate myo-
tubes (fusion index). Measurements of muscle colonies
were carried out by observers unaware of the genotypes of
the cells. Clonal cell lines were derived by 2 consecutive
rounds of subcloning carried out using limiting dilution.
Statistical analysis was done using the InStat program (v.
2.0, Graphpad Software, San Diego CA).
Immunostaining, immunoblotting, and β-Galactosidase 
assays
Antibodies included rabbit anti-desmin (ICN/Cappel,
Costa Mesa CA) used at a dilution of 1:500; rabbit anti-
p16INK4a (sc-1207, Santa Cruz Biotechnology, Santa Cruz
CA) used at 2 µg/ml, rabbit anti-p19ARF (Novus Biologi-
cals, Littleton CO) used at 0.5 µg/mL, and mouse anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
used at 2 µg/ml (Research Diagnostics, Flanders NJ). Anti-
body binding was visualized using a horseradish peroxi-
dase-based detection system (Vectastain Elite kit; Vector
Laboratories) with diaminobenzidine substrate. Detec-
tion of Sca-1 and Bcl-2 was performed as previously
described [4], except only a single mAb (clone E13-161.7;
Pharmingen Laboratories, San Diego CA) was used to
detect Sca-1.
Protein extraction from cultured cells and immunoblot-
ting was carried out as described [4].
To detect senescence- (or stress-) associated β-galactosi-
dase activity (SA-βGal) [10,11,13], cells were washed in
PBS, fixed for five minutes in 4% paraformaldehyde,
washed two times with PBS and incubated overnight at
37°C in fresh staining solution consisting of 1 mg of 5-
bromo-4-chloro-3-indolyl β-D-galactoside (X-Gal; stored
as a 20 mg/ml stock in DMSO) per ml / 40 mM citric acid/
sodium phosphate, pH 6.0 / 5 mM potassium
ferrocyanide /5 mM potassium ferricyanide /150 mM
NaCl /2 mM MgCl2.
p53, karyotyping, soft agar growth
To analyze p53 transcriptional activity, target cells were
transfected with the PG13-GFP reporter plasmid from
which expression of Green Fluorescent Protein (GFP) is
under control of a p53-dependent promoter consisting of
thirteen copies of the p53 consensus binding sequence
[33]. As a control for transfection efficiency, target cells
were simultaneously transfected with a plasmid on which
β-galactosidase is under control of a constitutively active
fragment of CMV promoter (BD Biosciences, San Diego
CA). FuGENE 6-mediated transfection was carried out
using supplier-provided protocols (Roche Applied Sci-
ences, Indianapolis IN), using 2 µg of the PG13-GFP
reporter plasmid and 0.5 µg of the control plasmid per 35
mm culture dish. At 72 hours after transfection, cultures
were switched into differentiation medium, and, after an
additional 48 hours, cells were examined for expression of
GFP by fluorescence microscopy. Finally, cells were para-
formaldehyde-fixed and immunostained for β-galactosi-
dase using a specific primary antibody (Molecular Probes,
Eugene OR) and a rhodamine F(ab)-conjugated second-
ary antibody (ICN/Cappel, Costa Mesa CA).
Induction of p53 by Actinomycin D was determined by
treating cells with 60 ng/ml of Actinomycin D for 8 hours.
Cells were collected for immunoblot analysis 16 hours
after the Actinomycin D had been removed and replaced
with fresh medium.
Karyotypes of colcemid-treated and fixed cells were deter-
mined essentially as in previous work [14,50], except that
chromosomes were not eosin-stained. Chromosomes of
20 – 30 cells of each genotype were counted in metaphase
spreads.
Soft agar assays to test for anchorage-independent growth
were performed as described [30]. For each assay, 2 × 104
cells were cultured per 6 cm dish in proliferation medium.
Induced cell death assays
Cultures of cloned, immortalized Bax-null and wild-type
myogenic cells were grown to near confluence in growth
medium, at which time fresh growth medium containing
adriamycin (doxorubicin, 1.7 µM), staurosporine (50
nM), or no addition as a control was added. After 24 h, the
number of viable cells in each culture was determined as
above. Untreated Bax-null and Bax-positive cultures had
statistically identical numbers of cells, and the number of
cells in the adriamycin- and staurosporine-treated cultures
was converted to percentage of the untreated control cell
number.
ATPase stain
Sections (10 µm) were prepared [4,51] from frozen soleus
muscles dissected from Bax-null and Bax-positive litter-
mates at seven weeks of age. Muscles were examined from
three pairs of gender- and age-matched littermates.
ATPase staining of muscle sections at pH 10.2 and 4.3 was
used to identify fast and slow myofibers [52]. The cross-
sectional area of every fast and slow myofiber within a 0.3
mm2 area of each soleus was determined by computer-
assisted morphometry (NIH Image program, http://
rsb.info.nih.gov/nih-image/), with average cross-sectional
areas, average density of myofibers, and statistical com-
parisons determined with the InStat program.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/1
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